Veradermics

MANE

The current Veradermics (MANE) market capitalization is approximately $1.92B, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, Veradermics's market cap fluctuates with changes in its share price and share count. Last updated: March 9, 2026 at 6:34 PM Eastern Time

Veradermics (MANE) does not currently pay a dividend. Over the last twelve months (LTM), the company paid $0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future.

Analyst assessments of whether Veradermics (MANE) consensus price target is overvalued or undervalued are generally expressed relative to consensus valuation frameworks and price targets, rather than as an absolute judgment.Current share price: $51.32Consensus price target: $78.33Implied return: +52.64% An implied return above current levels indicates that, on average, analysts view the stock as trading below their estimated fair value. Conversely, an implied return below current levels suggests the stock may be fully valued or priced above consensus expectations. This content is for informational purposes only and does not constitute investment advice. Last updated: March 9, 2026 at 4:59 PM Eastern Time

Based on the latest available analyst coverage, Veradermics (MANE) currently carries a Buy consensus rating. Analysts' average MANE price target is $78.33. Relative to the current share price of $51.32, this suggests a potential price change of approximately +52.64%. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: March 9, 2026 at 4:59 PM Eastern Time

Like other publicly traded stocks, Veradermics (MANE) shares are bought and sold on stock exchanges such as NYSE and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for Veradermics (MANE) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.

At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add MANE to your watchlist.

Veradermics trades under the ticker symbol MANE on the NYSE stock exchange. The ticker MANE is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.

As of the most recently reported period, Veradermics (MANE) employs approximately 19 people worldwide. Reported employee figures may fluctuate over time due to hiring activity, restructuring, automation initiatives, or changes in business strategy. Headcount data is typically disclosed in company filings and reflects full-time employees unless otherwise stated. Last updated: March 9, 2026 at 6:34 PM Eastern Time

Veradermics (MANE) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest Veradermics (MANE) stock peers based on overlapping products, services, and competitive dynamics:Amylyx Pharmaceuticals (AMLX)Protagonist Therapeutics (PTGX)Biogen (BIIB)Novavax (NVAX)Bristol-Myers Squibb (BMY)Structure Therapeutics (GPCR)Royalty Pharma (RPRX)Eli Lilly and (LLY)Merck (MRK)Pfizer (PFE) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to Veradermics.